
OTCMKTS:ESLOY
3 expert ratings on EssilorLuxottica (ESLOY) in the last 12 months: 2 Buy, 1 Hold, 0 Sell. Latest rating: TOP PICK by Martin Cobb, ASIP on Sep 17, 2026.
Doesn't like META, but a way around that is to own this name instead. Makes the virtual reality glasses for META. Essilor does the lenses, and Luxottica does the frames. Less volatility. Up this year ~48-49%.
Shows that you don't have to own the big names. You can own names that have access to what's happening in AI and virtual reality, diversify your portfolio, and lessen the volatility risk.
Lenses plus frames. Has a lock on the whole value chain. Purchase of Grant Vision will dramatically change its business over the next several years. Use of lenses has increased because of aging demographics plus faster eye deterioration from computer screens. Also a fashion statement. Great technology. Yield is 1.7%.
(Analysts’ price target is $109.40)EssilorLuxottica is a American stock, trading under the symbol ESLOY (previously ESLOY-OTC on Stockchase) on the US OTC (ESLOY). It is usually referred to as OTC:ESLOY or ESLOY
3 expert ratings on EssilorLuxottica (ESLOY) in the last 12 months: 2 Buy, 1 Hold, 0 Sell. Latest rating: TOP PICK by Martin Cobb, ASIP on Sep 17, 2026. Read the latest stock experts' ratings for EssilorLuxottica.
EssilorLuxottica was recommended as a Top Pick by Martin Cobb, ASIP on 2026-09-17. Read the latest stock experts ratings for EssilorLuxottica.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for EssilorLuxottica.
EssilorLuxottica is followed by 33 investors on Stockchase and is a trending stock that is worth watching.
On 2026-09-16, EssilorLuxottica (ESLOY) stock closed at a price of $83.07.
Lenses + Frames. 800-pound gorilla in eyecare throughout the world. Valuation is in very interesting territory. Tariffs, exchange rates, Ray-Ban smart glasses under pressure. Long-term demographics of people needing corrective lenses mean it's well-positioned. (Price target in euros.) Yield is 2.80%.
(Analysts’ price target is $238.90)